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The current study evaluated the stability potential of a transdermal patch composed of
eserine and pralidoxime chloride for prophylaxis against ()-anatoxin A poisoning. The
drug combinations were fabricated in an adhesive matrix system supported by a backing
membrane and attached to a temporary release liner. Stability testing of the optimized
formulation was established for 6 months under accelerated study conditions as per In-
ternational Conference on Harmonisation guidelines. Results obtained after 6 months
showed that the optimized patch formulation was stable with respect to drugs content, pH,
diffusion, visual inspection, and other analytical parameters.
Copyright ª 2014, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license. 1. Introduction
The notion of stability in pharmaceutics is understood as the
ability of a pharmaceutical product to maintain its properties
within the specified limits during its declared shelf life [1]. In
order to define the shelf life for a drug, investigations/tests
must be performed, according to a prescheduled program,eutical Technology, Defe
l.com (P. Chattopadhyay)
inistration, Taiwan. Publiresulting in information about various aspects of stability
(chemical, physical, andmicrobiological) [2]. Essential goals of
stability test performance are as follows: (1) selection of
adequate formulation and primary packagingmaterial; and (2)
determination of shelf life and storage conditions for the drug.
()-Anatoxin A, a guanidinemethyl phosphate ester iso-
lated from the freshwater cyanobacterium (blue-green algae),
produces its effects primarily by binding selectively andnce Research Laboratory, Tezpur 784 001, Assam, India.
.
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nervous system in rat brain membranes, where it acts as a
potent agonist but it is not hydrolyzed by cholinesterase.
Eserine and 2-PAM are one of a number of medical drugs
against certain psychochemical warfare agents. In vivo pre-
treatment with eserine and high concentrations of pralidox-
ime chloride (2-PAM) are the only effective antagonists against
a lethal dose of ()-anatoxin A poisoning [3]. Again, the pro-
tective effects of a nonselective muscarinic antagonist (atro-
pine), a cholinesterase-reactivating oxime (2-PAM), and two
reversible acetyl cholinesterase inhibitors (physostigmine and
pyridostigmine) against fonofos and phosphamidon induced
lethality in 24 h Artemia is well documented. The concentra-
tions of eserine and 2-PAM were selected based on the clini-
cally available plasma concentrations in human, without
considerable dermal irritation, skin sensitization and acute
dermal toxicity [4]. An eserine transdermal delivery system is
an attractive option given the potent nature of the drug and
bypass of the hepatic first-pass elimination effect. A
controlled-release device of eserine is desirable because it can
avoid the need for multiple doses, improve drug stability, and
release eserine in a controlled fashion. For this reason, eserine
has been suggested as an alternative prophylactic against
Such Lethal poisoning because it is an unquaternized carba-
mate that penetrates the central nervous system [5]. However,
eserine has a short plasma half-life and a narrow therapeutic
index, which limited its clinical use in humans and needs the
use of a sustained release formulation [6]. For this reason, we
developed a sustained-release, combinational, prophylactic
transdermal drug-in-adhesivematrix type therapeutic system
containing eserine and 2-PAM for the delivery to the skin.
In the present study, we evaluated the stability potential of
a transdermal patch formulation composed of eserine and 2-
PAM developed at our laboratory for prophylaxis against
()-anatoxin A poisoning at different time intervals according
to the International Conference on Harmonisation (ICH)
guidelines.Table 1 e Points of analysis.
Points Analysis
1 Eserine content in transdermal
patch
2 2-PAM content in transdermal
patch
3 Surface pH
4 Diffusion study
5 Visual inspection
6 Attenuated total reflectance
7 Differential scanning calorimetry
8 X-ray diffraction
2-PAM ¼ pralidoxime chloride.2. Materials and methods
2.1. Reagents
Eserine and 2-PAMwere provided by SigmaeAldrich (St. Louis,
MO, USA). Pressure-sensitive adhesives were obtained from
Henkel Corporation (Bridgewater, NJ, USA). Backing polyester
film laminate and release liner were kindly donated as a gift
sample by 3M (St. Paul, MN, USA). All reagents and solvents
used were of analytical grade and used as received.
2.2. Preparation of drugs-in-adhesive matrix type
transdermal patches
Drugs-in-adhesive matrix type transdermal patches contain-
ing eserine and 2-PAM were prepared with the blends of two
pressure-sensitive adhesives in different volume ratios and
different concentrations of permeation enhancer until a ho-
mogeneousmixturewas obtained. Themixturewas degassed,
cast on drug-impermeable backing membrane, dried, and
finally attached with a protective release liner.2.3. Accelerated stability testing study
The accelerated stability testing study of the best optimized
transdermal patch was performed for 6 months, according to
the ICH guidelines [7] under the following conditions: 40  2C
temperature and 75 5% relative humidity (RH) to confirm the
stability potential of the drugs present in the best optimized
formulation. The parameters determined during the stability
study are listed in Table 1. Points of analysis 1 and 2 gave the
eserine and 2-PAM content in best optimized transdermal
patchformulation, respectively. SurfacepH,diffusionanalysis,
visual inspection, attenuated total reflectance (ATR), differen-
tial scanning calorimetry (DSC), and X-ray diffraction (XRD)
analysis of the samples were carried out at Points 3e8,
respectively. The samples were withdrawn periodically (0, 2
weeks, 1 month, 2 months, 3 months and 6 months) and
evaluated for different points of analysis. After 6 months, all
points of analysis were carried out to assess the physico-
chemical stability of the optimized drugs-in-adhesive trans-
dermal patchunder accelerated study conditions. The adopted
study plan design including the points of analysis under the
accelerated stability study conditions is shown in Table 2.2.4. Drug content uniformity
Samples consisting of optimized drugs-in-adhesivematrix type
transdermal patches were stored according to the study plan
design to determine the effect of changes indrug content on the
stability of the formulations. The patches composed of eserine
and 2-PAM were transferred to a 100-mL volumetric flask and
extracted with ethanol. The flask was shaken forw2 hours by
mechanicalmeans and thencentrifugedat 6000g for 10minutes
and the supernatant was collected. The supernatant was then
transferred to a 10-mL volumetric flask and dilutedwithmobile
phasetocomplete thevolume.All sampleswerefilteredthrough
a 0.45-mmfilter before injection on the high-performance liquid
chromatography system. The simultaneous chromatographic
determination and estimation of eserine and 2-PAM present in
drugs-in-adhesive matrix type transdermal patches were per-
formed using the method developed and validated in our labo-
ratory, as per the ICH guidelines, using an isocratic mode of
elution and reverse-phase liquid chromatography under the
following chromatographic conditions [8]: (1) composition of
mobile phase: acetonitrile: 10 mM potassium dihydrogen
phosphate and 10 mM heptane-1-sulfonic acid sodium salt
Table 2 e Accelerated stability testing study plan design
including the points of analysis.
ICH conditions Time period (mo)
0 0.5 1.0 2.0 3.0 6.0
(40  2C)/75  5% RH 1e8 1e5 1e5 1e5 1e5 1e8
ICH ¼ International Conference on Harmonisation; RH ¼ relative
humidity.
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 2 ( 2 0 1 4 ) 2 6 4e2 7 0266monohydrate inwater (adjusted to pH3.0with orthophosphoric
acid) at a ratio of 30:70, v/v, respectively; (2) mobile phase flow
rate: 1.0 mL/min; (3) injection volume: 20 mL; (4) detection
wavelength: 238 nm with a UV detector; and (5) column: C18
column (CHOMASIL, particle size 5 mm, 250 mm  4.6 mm in-
ternal diameter).
2.5. Surface pH
The patches were kept in contact with casting solvent for 30
minutes. The surface pH of the patch wasmeasured bymeans
of a potentiometer [9].
2.6. Diffusion study
The ex vivo skin permeation through depilated rat abdominal
skin of the optimized transdermal patch kept under acceler-
ated stress conditions was conducted using a modified Franz
diffusion cell apparatus at different periods of time.
2.7. Visual inspection
All the prepared patches were visually inspected for shape,
clarity, smoothness, homogeneity, stickiness, uniformity and
flexibility.
2.8. ATR analysis
ATR analysis (Bruker, Bremen, Germany) of an optimized
transdermal patch before initiation and after completion of
the stability study was carried out to assess the integrity and
compatibility of the drugs with the pressure-sensitiveTable 3 e Points of analysis performed in optimized transderm
conditions.
Points of analysis T
0 0.5 1.0
1a 87.05  2.53% 89.31  2.15% 83.61  1.63
2a 91.40  2.09% 89.77  2.79% 90.98  4.86
3b 6.1 6.5 6.1
4b 89.65% in 72 h for
eserine 94.35% in
72 h for 2-PAM
88.62% in 72 h for
eserine 95.02% in
72 h for 2-PAM
90.51% in 7
eserine 96.5
72 h for 2-P
5 Complies Complies Complies
6 Complies d d
7 Complies d d
8 Complies d d
d ¼ not determined; 2-PAM ¼ pralidoxime chloride.
a Indicates mean values of three observations, along with their standard
b Single value.adhesive component in the drugs-in-adhesives matrix type
transdermal patch. The sample was placed in the sample
holder and spectral scanning was undertaken in the wave
number region between 4000 cm1 and 500 cm1 at a resolu-
tion of 4 cm1 and scan speed of 2 mm/s.
2.9. DSC analysis
DSC analysis was performed on the optimized transdermal
patch before and after the stability study. Initially, the mois-
ture was removed by heating the samples and then each
sample was accurately weighed into a platinum crucible 40-mL
aluminum pan under hermetically sealed conditions, where
a-alumina powder was used as a reference. Thermograms
were recorded from 30C to 500C at the heating rate of 10C/
min under a constant flow of an inert nitrogen gas atmo-
sphere at a flow rate of 20 mL/min. These analyses were done
on a PerkineElmer Instruments Pyris-Diamond TG/DTA
(Osaka, Japan).
2.10. XRD studies
X-ray diffractograms were recorded for optimized trans-
dermal patches before and after the stability study using an X-
ray diffractometer (X-pert Pro; PANalytical, Netherlands)
equipped with Ni-filtered CuKa radiation (q ¼ 1.5418 A˚), at
30 kV and 15 mA. The samples were mounted on a sample
holder and XRD scans were recorded up to 2 q plane in the
angle range of 1e60 at a scan speed of 1/min to estimate the
crystallinity of the samples.3. Results and discussion
The best optimized drugs-in-adhesive matrix type prophylac-
tic transdermal patches composed of eserine and 2-PAMwere
subjected to accelerated stability testing as per ICH guidelines.
The patches were stored at a temperature of 40  2C and
75  5% RH for 180 days (6 months). The accelerated stability
testing study data of the best-optimized formulation is shown
in Table 3. The optimized formulation was found to be stableal patch formulation during accelerated stability testing
ime period (mo)
2.0 3.0 6.0
% 90.14  1.71% 88.80  3.40% 84.84  2.71%
% 93.17  2.49% 88.08  3.58% 90.31  4.40%
6.2 6.6 6.3
2 h for
8% in
AM
88.31% in 72 h
for eserine 93.05% in
72 h for 2-PAM
87.44% in 72 h for
eserine 91.12% in
72 h for 2-PAM
86.13% in 72 h for
eserine 96.71% in
72 h for 2-PAM
Complies Complies Complies
d d Complies
d d Complies
d d Complies
deviation values.
Fig. 1 e Attenuated total reflectance spectra of optimized transdermal patch (A) at 0 months and (B) at 6 months under
accelerated stability testing conditions.
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mulative percentage release, and by visual inspection.
Furthermore, in order to assess the integrity, compatibility
and stability of the final optimized formulations, the samples
were analyzed by ATR, DSC and XRD. For this purpose, 0 and 6
months ATR, DSC and XRD were performed in order to rule
out any alteration in drugs and excipient compatibility
studies, changes in glass transition profile, and to access the
appearance of crystallinity during the stability period. After 6
months, ATR, DSC and XRD revealed that there were no
physicochemical changes under such conditions, as sup-
ported by the figures generated from the instruments,
showing the integrity of the product.
3.1. Drug content uniformity of the patches
Results obtained after 0e6 months storage are presented in
Table 3. The drug content of eserine and 2-PAM in optimizedtransdermal patches ranged from 83.61  1.63% to
90.14 1.71% and 88.08 3.58% to 93.17 2.49%, respectively.
There were no significant changes in drug content of eserine
and 2-PAM in optimized transdermal patches during the
study. Observed variations were due to the drug-loading
process. Drug contents were found to be uniform with rela-
tively low standard deviation values. The results of content
uniformity studies clearly indicate that the drug was uni-
formly distributed throughout the pressure-sensitive adhe-
sives (PSAs) matrix. Temperature and RH did not show any
significant effect on drug content uniformity of the trans-
dermal patches. None of the main and other degradation
products of eserine and 2-PAM were obtained in the opti-
mized transdermal patches during high-performance liquid
chromatography analysis. The drug content in the trans-
dermal patches was stable under the accelerated stress
conditions during the study. Minute variations in drug con-
tent were observed, but within allowed limits.
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The surface pH of optimized transdermal patch solution was
found to be in the range of 6.1e6.6, which indicated the
absence of skin irritancy and stability of the product. No sig-
nificant changes in pH valuewere observed in 6months. Thus,
the pH of the formulation was stable throughout the study.
3.3. Diffusion study
The ex-vivo skinpermeationprofilesof eserineand2-PAMwere
investigated by modified Franz diffusion cell apparatus at
different periods of time. The cumulative amounts of released
drugs remained stable at 40C/75% RH for 6 months, with a
small amount of variation in completedrug releaseprofileat 72
hours. The observed variation may have been due to the vari-
ation in theoreticaldrug loadingduring the fabricationprocess.
3.4. Visual inspection
There was no alteration in the visual character of the opti-
mized transdermal patch during the period of analysis,Fig. 2 e Differential scanning calorimetry thermogram of optim
under accelerated stability testing study conditions.especially in terms of shape, clarity, smoothness, homoge-
neity, stickiness, uniformity and flexibility. No red tint color-
ation over the patch formulation was observed under
accelerated stress conditions for >6 months. The red tint
coloration appeared due to the air, heat, light, traces ofmetals,
and moisture sensitivity of eserine [10]. This might be due to
the rigidity of the adhesive matrix system that compactly
entrapped the drug moiety into its matrix, by preventing the
presence of free eserine over the surface of the matrix. It was
also evident with DSC and XRD analysis of the optimized
patch that the drugs were homogeneously dispersed over the
adhesive matrix system. No corresponding DSC and XRD
peaks of pristine drugs were found, indicating the absence of
free drugs.3.5. ATR analysis
ATR analysis of optimized transdermal patches was per-
formed before and after the stability study (Fig. 1A and B). The
ATR profiles of optimized transdermal patches remained
stable during storage under accelerated stress conditions. Weized transdermal patch (A) at 0 months and (B) at 6 months
Fig. 3 e X-ray diffractograms of optimized transdermal patch (A) at 0 months and (B) at 6 months under accelerated stability
testing study conditions.
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analysis. The observed variation was probably due to the
drug-loading process and complete loss of organic solvents
during storage.3.6. DSC and XRD analysis
DSC (Fig. 2A and B) and XRD (Fig. 3A and B) profiles
of optimized transdermal patches before and after stability
testing did not show any significant changes, indicating
the stability and non-crystallinity of the samples during
storage.4. Conclusion
The study showed successful results, and the optimized
transdermal patches composed of eserine and 2-PAM were
stable for 6 months at 40C/75% RH. No significant changes in
test parameters were noticed. To the best of our knowledge,this has not been shown previously for this type of product.
The patches used in this study gave a complete drug-release
profile for a period of 72 hours. The optimized prophylactic
transdermal patch used in the study constitutes an inter-
esting formulation for prophylaxis against ()-anatoxin A
poisoning.Conflicts of interest
The authors declare that they have no conflicts of interest to
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